Company profile

Ticker
ABBV
Exchange
Website
CEO
Richard A. Gonzalez
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
320375147

ABBV stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

4 Nov 20
5 Dec 20
31 Dec 20

News

Quarter (USD) Sep 20 Jun 20 Mar 20 Sep 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Abbvie earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
27 Nov 20 Timothy J. Richmond Common Stock, $0.01 par value Sell Dispose S No 105 51,990 5.46M 0
27 Nov 20 Timothy J. Richmond Common Stock, $0.01 par value Option exercise Aquire M No 51.42 51,990 2.67M 51,990
27 Nov 20 Timothy J. Richmond Option Common stock Option exercise Dispose M No 51.42 51,990 2.67M 0
20 Nov 20 Henry O Gosebruch Common Stock, $0.01 par shar Sell Dispose S No 99.49 33,100 3.29M 20,006
20 Nov 20 Henry O Gosebruch Common Stock, $0.01 par share Sell Dispose S No 98.83 6,900 681.93K 53,106
16 Nov 20 Carlos Alban Common Stock, $0.01 par value Sell Dispose S No 100 115,830 11.58M 114,899
16 Nov 20 Carlos Alban Common Stock, $0.01 par value Option exercise Aquire M No 35.88 115,830 4.16M 230,729
16 Nov 20 Carlos Alban Option(Right to buy) Common Stock Option exercise Dispose M No 35.88 115,830 4.16M 0
12 Nov 20 Richard A Gonzalez Common Stock, $0.01 par value Sell Dispose S No 97.4889 16,171 1.58M 318,642
12 Nov 20 Richard A Gonzalez Common Stock, $0.01 par value Sell Dispose S No 97.0615 177,983 17.28M 334,813
67.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2196 2246 -2.2%
Opened positions 113 252 -55.2%
Closed positions 163 97 +68.0%
Increased positions 993 1182 -16.0%
Reduced positions 830 637 +30.3%
13F shares
Current Prev Q Change
Total value 103.96B 117.94B -11.9%
Total shares 1.18B 1.2B -1.7%
Total puts 18.37M 18.5M -0.7%
Total calls 12.67M 16.92M -25.1%
Total put/call ratio 1.5 1.1 +32.6%
Largest owners
Shares Value Change
Vanguard 144.33M $12.64B -2.1%
BLK Blackrock 122.02M $10.69B -1.1%
STT State Street 78.21M $6.85B -1.9%
Capital Research Global Investors 40.8M $3.57B -11.5%
TROW T. Rowe Price 32.74M $2.87B -21.6%
FMR 30.26M $2.65B -3.5%
JPM JPMorgan Chase & Co. 29.19M $2.54B +1.9%
Geode Capital Management 26.14M $2.28B -9.8%
NTRS Northern Trust 24.36M $2.13B +0.9%
BRK.A Berkshire Hathaway Inc. - 21.26M $1.86B NEW
Largest transactions
Shares Bought/sold Change
BRK.A Berkshire Hathaway Inc. - 21.26M +21.26M NEW
TROW T. Rowe Price 32.74M -9.04M -21.6%
Renaissance Technologies 13.47M -5.55M -29.2%
Capital Research Global Investors 40.8M -5.3M -11.5%
DB Deutsche Bank 11.98M +3.43M +40.1%
Vanguard 144.33M -3.05M -2.1%
BCS Barclays plc - 4.91M +2.97M +152.6%
Citadel Advisors 479.92K -2.95M -86.0%
Geode Capital Management 26.14M -2.82M -9.8%
Nordea Investment Management Ab 3.22M -2.75M -46.1%

Financial report summary

?
Risks
  • The expiration or loss of patent protection and licenses may adversely affect AbbVie's future revenues and operating earnings.
  • AbbVie's major products could lose patent protection earlier than expected, which could adversely affect AbbVie's future revenues and operating earnings.
  • AbbVie's research and development efforts may not succeed in developing and marketing commercially successful products and technologies, which may cause its revenues and profitability to decline.
  • AbbVie's biologic products are subject to competition from biosimilars.
  • Significant safety or efficacy issues could arise for AbbVie's products, which could have a material adverse effect on AbbVie's revenues and financial condition.
  • AbbVie is subject to numerous governmental regulations, and it can be costly to comply with these regulations and to develop compliant products and processes.
  • AbbVie is dependent on wholesale distributors for distribution of its products in the United States and, accordingly, its results of operations could be adversely affected if they encounter financial difficulties.
  • AbbVie has debt obligations that could adversely affect its business and its ability to meet its obligations.
  • Failure to attract and retain highly qualified personnel could affect AbbVie’s ability to successfully develop and commercialize products.
  • The pending acquisition of Allergan may not be completed on the currently contemplated timeline or terms, or at all, and may not achieve the intended benefits.
  • The indebtedness of the combined company following the consummation of the Acquisition will be substantially greater than AbbVie’s indebtedness on a standalone basis and greater than the combined indebtedness of AbbVie and Allergan prior to the announcement of the acquisition. This increased level of indebtedness could adversely affect the combined company’s business flexibility and increase its borrowing costs.
Management Discussion
  • AbbVie's strategy has focused on delivering strong financial results, advancing and investing in its pipeline and returning value to shareholders while ensuring a strong, sustainable growth business over the long term. The company's financial performance in 2019 included delivering worldwide net revenues of $33.3 billion, operating earnings of $13.0 billion, diluted earnings per share of $5.28 and cash flows from operations of $13.3 billion. Worldwide net revenues grew by 3% on a constant currency basis, primarily driven by revenue growth related to IMBRUVICA and VENCLEXTA as well as the continued strength of HUMIRA in the U.S. and newly launched immunology assets SKYRIZI and RINVOQ, offset by international HUMIRA biosimilar competition.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: adolescent, Advertising, allegedly, ankylosing, Biopharma, Brazil, BTL, China, CoolSculpting, CoolTone, cord, decided, denial, dermal, elezanumab, eligible, experienced, explore, Fast, filler, GEMINI, GmbH, HArmonyCa, induced, injury, Ireland, Israel, lead, lemzoparlimab, Luminera, Lupron, Medizinsysteme, misconduct, monoclonal, Orphan, presbyopia, reinstated, scale, soft, solution, spinal, taxable, teen, tissue, Track, Unlimited, vacated, Zeltiq, Zimmer
Removed: Alameda, appealing, Commissioner, Committee, dated, Department, discussed, encompassing, flat, fraudulent, Georgia, indenture, insurance, intervened, invalid, Lazaro, statute, stayed, Steering, Suarez, submission, trustee, Unimed, violate, violation

Patents

GRANT
Utility
Protein tyrosine phosphatase inhibitors and methods of use thereof
1 Dec 20
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
APP
Utility
CorrectedMethods for Treating HCV
26 Nov 20
The present invention features interferon-free therapies for the treatment of HCV.
APP
Utility
Ibrutinib Combination Therapy
26 Nov 20
Combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, with a second anticancer agent are provided.
APP
Utility
Methods of Treating Glioblastoma
26 Nov 20
The present disclosure provides a method for treating cancer in a patient harboring an EGFR-expressing tumor and/or tumor cell, such as glioblastoma, comprising the combination of (i) applying an AC electric field to a target area, wherein the target area comprises an EGFR-expressing tumor or cancer cell); and (ii) administering an effective amount of depatuxizumab mafodotin.
GRANT
Utility
Anti-CD40 antibody
24 Nov 20
The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.